Pentosan Polysulfate

PEPTIDES+ MEMBERS ONLY

INDICATIONS FOR USE

Pentosan Polysulfate (PPS) is used off-label and experimentally for its potential benefits in joint health, cartilage repair, and chronic inflammatory conditions. Originally FDA-approved for interstitial cystitis (oral formulation), PPS has gained interest in regenerative medicine—particularly in osteoarthritis and degenerative joint disease—due to its anti-inflammatory, anticoagulant, and disease-modifying properties.

ROUTE OF ADMINISTRATION

  • Subcutaneous Injection (off-label for joint and systemic use)

COMMON INITIAL DOSING REGIMENS

  • Subcutaneous protocols typically involve 2 mg/kg injected twice weekly for 3–6 weeks, often followed by maintenance doses administered weekly or monthly. 

MECHANISM OF ACTION

  • Pentosan Polysulfate is a semi-synthetic polysaccharide with structural similarities to glycosaminoglycans found in cartilage and connective tissue. It exhibits anti-inflammatory activity by inhibiting cytokines such as TNF-alpha and IL-1, reduces complement activation, and has mild anticoagulant properties.

  • In musculoskeletal applications, PPS may stimulate cartilage matrix production, improve synovial fluid viscosity, and decrease joint degeneration. It has been shown in veterinary use (particularly in equine and canine osteoarthritis) to enhance mobility and reduce pain.

COMMON SIDE EFFECTS

  • General: Headache, fatigue, or dizziness.

  • Gastrointestinal: Nausea, diarrhea, or abdominal discomfort.

  • Dermatologic: Bruising or delayed healing due to mild anticoagulant effects.

  • Injection Site: Mild redness, pain, or swelling.

  • Rare: Hematuria (blood in urine), elevated liver enzymes, or allergic reactions. Very rare reports of maculopathy with long-term high-dose oral use.

CONTRAINDICATIONS

  • Absolute: Known hypersensitivity to Pentosan Polysulfate. Active bleeding disorders or anticoagulant therapy.

  • Relative: Use with caution in patients with liver impairment, peptic ulcer disease, or upcoming surgical procedures. Regular monitoring may be necessary during prolonged treatment.

COMPARISON WITH OTHER AGENTS

  • Hyaluronic Acid Injections: These improve joint lubrication but do not offer disease-modifying properties. PPS may have broader regenerative effects by reducing inflammation and promoting cartilage repair.

  • NSAIDs: While NSAIDs provide symptom relief, PPS aims to address underlying joint degeneration and inflammation without GI or cardiovascular toxicity seen in chronic NSAID use.

  • Peptides (e.g., BPC-157, TB-500): These promote soft tissue healing and reduce inflammation. PPS may complement these agents in joint-specific protocols, with added benefits to cartilage and synovial structures.

EXPERIMENTAL TREATMENT DISCLAIMER:

  • Pentosan Polysulfate is FDA-approved only for oral use in the treatment of interstitial cystitis. All other uses—including injectable forms for musculoskeletal or regenerative applications—are considered experimental. Long-term safety data for off-label administration routes are limited. The patient acknowledges that this is an investigational therapy and accepts all associated risks.

MORE INFORMATION

  • FDA Safety Data Sheet not available

  • Smith MM. Pentosan Polysulfate, a Semisynthetic Heparinoid Disease-Modifying Osteoarthritic Drug with Roles in Intervertebral Disc Repair Biology Emulating the Stem Cell Instructive and Tissue Reparative Properties of Heparan Sulfate. Stem Cells Dev. 2022 [PubMed Link]

  • Siddiq MA. Efficacy and safety of pentosan polysulfate sodium in people with symptomatic knee osteoarthritis and dyslipidaemia: protocol of the MaRVeL trial. BMJ Open. 2024 [PubMed Link]

  • Siddiq MA. New therapeutic strategies in osteoarthritis. Joint Bone Spine. 2024 [PubMed Link]

  • Suranji Wijekoon HM. Anti-arthritic effect of pentosan polysulfate in rats with collagen-induced arthritis. Res Vet Sci. 2019 [PubMed Link]

  • Smith M. Pentosan Polysulfate Affords Pleotropic Protection to Multiple Cells and Tissues. Pharmaceuticals (Basel). 2023 [PubMed Link]

  • Herrero LJ. Pentosan Polysulfate: a Novel Glycosaminoglycan-Like Molecule for Effective Treatment of Alphavirus-Induced Cartilage Destruction and Inflammatory Disease. J Virol. 2015 [PubMed Link]

  • Krishnan R. Pentosan polysulfate sodium for Ross River virus-induced arthralgia: a phase 2a, randomized, double-blind, placebo-controlled study. BMC Musculoskelet Disord. 2021 [PubMed Link]

  • Solanki P. Repurposing pentosan polysulfate sodium as hyaluronic acid linked polyion complex nanoparticles for the management of osteoarthritis: A potential approach. Med Hypotheses. 2021 [PubMed Link]

  • Kumagai K. Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis--an open clinical trial. BMC Clin Pharmacol. 2010 [PubMed Link]

  • Ghosh P. The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthritis Rheum. 1999 [PubMed Link]

  • Stapledon CJ. Human osteocyte expression of Nerve Growth Factor: The effect of Pentosan Polysulphate Sodium (PPS) and implications for pain associated with knee osteoarthritis. PLoS One. 2019 [PubMed Link]

  • Ghosh P. Interactions of pentosan polysulfate with cartilage matrix proteins and synovial fibroblasts derived from patients with osteoarthritis. Osteoarthritis Cartilage. 1996 [PubMed Link]